Kezar Life Sciences Inc. (KZR)
NASDAQ: KZR
· Real-Time Price · USD
4.45
0.07 (1.60%)
At close: May 01, 2025, 3:59 PM
4.40
-1.12%
After-hours: May 01, 2025, 04:05 PM EDT
1.60% (1D)
| Bid | 4.35 |
| Market Cap | 32.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.74M |
| EPS (ttm) | -11.49 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | -0.59 |
| Analyst | Hold |
| Ask | 4.95 |
| Volume | 4,304 |
| Avg. Volume (20D) | 26,693 |
| Open | 4.50 |
| Previous Close | 4.38 |
| Day's Range | 4.42 - 4.62 |
| 52-Week Range | 3.62 - 9.20 |
| Beta | 0.61 |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 55
Stock Exchange NASDAQ
Ticker Symbol KZR
Analyst Forecast
According to 2 analyst ratings, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 102.25% from the latest price.
Stock Forecasts7 months ago
+42.1%
Kezar Life Sciences shares are trading higher afte...
Unlock content with
Pro Subscription
